475.4

+2.82%↑

SANES

9.98

+4.48%↑

SAF

290.6

+5.44%↑

BBVA

18.885

+4.45%↑

BNP

84.57

+4.32%↑

475.4

+2.82%↑

SANES

9.98

+4.48%↑

SAF

290.6

+5.44%↑

BBVA

18.885

+4.45%↑

BNP

84.57

+4.32%↑

475.4

+2.82%↑

SANES

9.98

+4.48%↑

SAF

290.6

+5.44%↑

BBVA

18.885

+4.45%↑

BNP

84.57

+4.32%↑

475.4

+2.82%↑

SANES

9.98

+4.48%↑

SAF

290.6

+5.44%↑

BBVA

18.885

+4.45%↑

BNP

84.57

+4.32%↑

475.4

+2.82%↑

SANES

9.98

+4.48%↑

SAF

290.6

+5.44%↑

BBVA

18.885

+4.45%↑

BNP

84.57

+4.32%↑

Kodu・Aktsiate loetelu・Metrovacesa SA

Metrovacesa SA

Suletud

SektorRahandus

11.05 -0.45

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.05

Max

11.2

Põhinäitajad
By Trading Economics
Sissetulek	-7.7M
Müük	66M
P/E Sektori keskmine	29.474 55.155
Kasumimarginaal	-11.69
Töötajad	214

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. apr 2026

Turustatistika
By TradingEconomics
Turukapital	1.7B
Eelmine avamishind	11.5
Eelmine sulgemishind	11.05

Uudiste sentiment

By Acuity

91%

15 / 441 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

11.45 / 11.7 Toetus ja vastupanu

Metrovacesa SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. märts 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Nike, RH, NCino

31. märts 2026, 22:35 UTC

Tulu

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1. apr 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31. märts 2026, 23:50 UTC

Omandamised, ülevõtmised, äriostud

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31. märts 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31. märts 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31. märts 2026, 23:21 UTC

Tulu

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31. märts 2026, 23:14 UTC

Market Talk

Tulu

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31. märts 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss Widens >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31. märts 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31. märts 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31. märts 2026, 21:35 UTC

Tulu

Nike Expects China Sales Down 20% in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31. märts 2026, 21:33 UTC

Tulu

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31. märts 2026, 21:32 UTC

Tulu

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31. märts 2026, 21:28 UTC

Tulu

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31. märts 2026, 21:26 UTC

Tulu

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31. märts 2026, 21:25 UTC

Tulu

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31. märts 2026, 21:24 UTC

Market Talk

Tulu

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31. märts 2026, 21:22 UTC

Tulu

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31. märts 2026, 21:22 UTC

Tulu

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31. märts 2026, 21:21 UTC

Tulu

Nike's Digital Channel Still Too Promotional, CFO Says

31. märts 2026, 21:20 UTC

Tulu

Nike CEO: Converse Remains Important to Portfolio

Võrdlus sarnastega

Hinnamuutus

Metrovacesa SA Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Metrovacesa SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

11.45 / 11.7Toetus ja vastupanu

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

15 / 441 Pingereas Rahandus

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Metrovacesa SA

Metrovacesa S.A. operates as a real estate development company in Spain. The company develops and sells residential and commercial premises, as well as sells land. Metrovacesa S.A. was founded in 1918 and is based in Madrid, Spain.

Muud aktsiad sektorist

LVMH Moet Hennessy Louis Vuitton SE.

475.4

↑ +2.82%

SANES

Banco Santander SA

9.98

↑ +4.48%

SAF

Safran SA.

290.6

↑ +5.44%

BBVA

Banco Bilbao Vizcaya Argentaria SA

18.885

↑ +4.45%

BNP

BNP Paribas SA

84.57

↑ +4.32%

Metrovacesa SA

Ülevaade

Aktsiahinna muutus

Põhinäitajad

Dividendid

Turustatistika

Uudiste sentiment

Tehniline skoor

Metrovacesa SA Graafik

Seotud uudised

Võrdlus sarnastega

Metrovacesa SA Prognoos

Hinnangu Konsensus

Tehniline skoor

Sentiment

Finantsandmed

Ettevõttest Metrovacesa SA

Muud aktsiad sektorist